Washington D.C. [USA], Apr. 7 (ANI): Patients on HeartMate 3 have fewer blood-related events than those on HeartMate II, according to a recent study. A six-month analysis of the pivotal MOMENTUM 3 ...

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than ...

SAN DIEGO — Patients with advanced heart disease who received the HeartMate 3 left ventricular assist device had fewer clotting and bleeding events at 6 months than similar patients who received the ...

ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...

NEW ORLEANS -- The HeartMate 3 left ventricular assist device's (LVAD) safety and outcome advantage over its predecessor held up in the final analysis of the MOMENTUM 3 trial. With the full complement ...

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

Good news for the HeartMate 3 (Abbott Cardiovascular) as a bridge to heart transplantation: in the 2 years following US Food and Drug Administration approval of the left ventricular assist device ...

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than ...

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for ...

Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...

There are more people in need of new hearts than there are hearts available — that's a big reason companies like Abbott Laboratories and Medtronic sell advanced implantable pumps called ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.